arrow
L

Ladislava Sebkova

pugliese-ciaccio hospital
H指数:14
被引数:1,525

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real‑world safety and efficacy of biological agents in inflammatory bowel disease: a one-year post-marketing pharmacovigilance observational study in the Calabria region

炎症性肠病中生物制剂的真实世界安全性与有效性:卡拉布里亚地区一项为期一年的上市后药物警戒观察性研究

2025-08-190
OA
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study
2024-11-271
OAAI
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
2024-01-256
PRE
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study
2023-03-026
PRE
Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]

妊娠期间因炎症性肠病而进行的手术: ECCO赋予多中心病例系列的母亲和后代结果 [Scar研究]

2022-04-049
OA
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy
2021-12-273
PREAI
Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study
2021-05-270
PRE
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers

Vedolizumab在炎症性肠病门诊患者的实际治疗中是有效且安全的: 一项在原发性炎症性肠病中心进行的多中心观察性研究

2019-08-0123
PREAI
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
2018-03-01141
OAAI
Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
2010-10-01394
OAAI